about
Appetite suppressants and primary pulmonary hypertension in the United KingdomRegulatory challenges for new drugs to treat obesity and comorbid metabolic disordersThe GLP-1 agonist, liraglutide, as a pharmacotherapy for obesityThe effect of fenfluramine on the pulmonary disposition of 5-hydroxytryptamine in the isolated perfused rat lung: a comparison with chlorphentermineStructure and function of serotonin G protein-coupled receptors.Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertensionPulmonary hypertension's variegated landscape: a snapshot.Dietary pulmonary hypertension.Chinese medicines for slimming still cause health problems.Epidemics of vascular toxicity and pulmonary hypertension: what can be learned?Primary pulmonary hypertension: the pressure rises for a gene.Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstrictionAppetite suppressants and pulmonary hypertension.The utility of animal models to evaluate novel anti-obesity agents.Valvular heart disease with the use of fenfluramine-phentermine.Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth.Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study.Single-blind, placebo controlled randomised clinical study of chitosan for body weight reductionPulmonary hypertension, hyperthyroidism, and fenfluramine: a case report and review.Genomics of pulmonary arterial hypertension: implications for therapy.A review of late-stage CNS drug candidates for the treatment of obesity.The unrelenting fall of the pharmacological treatment of obesity.Reducing the risk of obesity: defining the role of weight loss drugs.Stimulants and the lung : review of literature.Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension.Fenfluramine-induced gene dysregulation in human pulmonary artery smooth muscle and endothelial cellsClinical studies with dexfenfluramine: from past to future.Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary arteryInternational Primary Pulmonary Hypertension Study.Rapid clot formation and abnormal fibrin structure in a symptomatic patient taking fenfluramine--a case report.Influence of a combination of herbs on appetite suppression and weight loss in rats.Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels.Risks associated with herbal slimming remedies.Effects of dexfenfluramine on aristolochic acid nephrotoxicity in a rat model for Chinese-herb nephropathy.The pulmonary hypertensive fawn-hooded rat has a normal serotonin transporter coding sequence.A Review on Pharmacological Properties of Zingerone (4-(4-Hydroxy-3-methoxyphenyl)-2-butanone)
P2860
Q24563207-73503FED-A18F-45B4-813D-2BB0D2428B2CQ24658031-0753338A-0197-416F-AEBE-63B5BB181C03Q26765609-DD6D9667-178D-481B-8521-B0A4E325FB27Q28373184-B8E52669-C7BA-49D3-9F0D-0F092575CC74Q30382524-8861DDDA-E947-48BE-9198-555BFF7A4D8CQ33634204-15B6C810-D7FF-416E-B7D6-AB61F62AEFB9Q33738561-663DBFB2-793C-4D53-9170-A1923AAB342FQ33789022-4D7FFC8D-5CE0-497D-9094-7C14E7BF77A1Q33809601-082BB373-F910-4D8A-AB63-ED42D84C0592Q33836156-D1C4DA7F-4D0E-4F1B-B07B-72578CBCAC38Q34193231-7E0050F8-8050-47E7-8BE3-49597543848AQ34913082-9DEE8A18-DAF0-4DBB-9846-D898EE11E614Q35577164-D4551CA6-937F-4186-8A64-0BAEE8B546B9Q35589958-D432C6CF-D648-4A62-9BC0-3B4CCB2E0991Q35594782-8FCE23BE-1653-4F08-A10A-C4B566419338Q35787736-096F6380-3290-4B0D-9390-BB5537E4329FQ36380164-7D564FF6-67A8-4B57-B855-20894DC4A4E7Q36446366-CDE435F7-DD24-4674-84A4-3FF2DE0CBEDEQ36784255-C7F5E581-FABC-4B69-9A63-672B41D2289EQ37452405-056F837F-E018-4453-8693-D583CE1F995CQ37992857-383314D9-CC26-4F20-98A3-494FB525EC5DQ38107134-77D9D19C-CB12-44C6-9D16-124377D007B2Q38109836-CF1352C6-7A54-43FC-ADE0-1C794A610D0FQ38113985-CBFD5E71-8D88-4470-A9B7-9F5B1DDE7B14Q38167630-6EA887B4-4232-48E5-B0BC-B8E8A19921CCQ38803346-2EDA0C3B-C86D-4C58-B842-63DCB8B77287Q39385317-49EA77F5-BD28-419F-817B-1B36DFFC60D1Q40966850-1539D4E7-1B69-4BFE-97BF-5A2179D7A69AQ42235624-99915FE0-DA3F-4F91-9457-1A5F9800C49FQ42394719-E9784636-971E-4C31-93C3-1F78310FD023Q43626057-5E5593F7-AEE7-4B22-89E4-F0C38F60A04BQ43644870-D5C89B31-BFB0-4FF5-BD83-B11FAAAF2497Q43678620-04111D77-E3C3-4AA3-962D-B09CF38C6299Q44296362-69323CED-0890-4452-94F7-48578DE703A7Q44405520-4B6B42C4-B979-410D-88A1-57246ACFBF8FQ47708585-986B3A7A-031D-4BFA-A6A6-7F3697E4E23AQ59121326-6B5DDB7A-2005-4C8A-908F-73C2361FD9D0
P2860
description
1993 nî lūn-bûn
@nan
1993 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Primary pulmonary hypertension and fenfluramine use
@ast
Primary pulmonary hypertension and fenfluramine use
@en
Primary pulmonary hypertension and fenfluramine use
@nl
type
label
Primary pulmonary hypertension and fenfluramine use
@ast
Primary pulmonary hypertension and fenfluramine use
@en
Primary pulmonary hypertension and fenfluramine use
@nl
prefLabel
Primary pulmonary hypertension and fenfluramine use
@ast
Primary pulmonary hypertension and fenfluramine use
@en
Primary pulmonary hypertension and fenfluramine use
@nl
P2093
P2860
P356
P1476
Primary pulmonary hypertension and fenfluramine use
@en
P2093
P2860
P304
P356
10.1136/HRT.70.6.537
P407
P577
1993-12-01T00:00:00Z